Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2522)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF TRADING OF THE FIRST BATCH OF DATA

Reference is made to the announcement by Jiangxi Rimag Group Co., Ltd. (the "**Company**") dated April 2, 2025 in relation to the Company's first batch of Annotation Data of CT Chest Lesions (CT胸部病變標注數據) (the "**Datasets**") launched on the Shanghai Data Exchange (the "**Announcement**"). Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless otherwise stated.

The Board is pleased to announce that on August 25, 2025, the Datasets officially passed the compliance review by the Beijing International Data Exchange (the "**BIDE**") and was successfully launched on it with the product ID of PD2025082117370118. Beijing Rimag Information, a subsidiary of the Company acting as the data provider, entered into a tripartite cooperation contract for data trading (the "**Tripartite Cooperation Contract for Data Trading**") with a company engaged in data technology and application (the "**Data User**") and Beijing International Data Exchange Co., Ltd., and on September 1, 2025, pursuant to the Tripartite Cooperation Contract for Data Trading, the Group completed the trading of the first batch of data with the Data User (the "**Trading**").

The Trading aims to promote the standardized integration and market-based trading of data elements. The Trading was conducted on the BIDE, which ensured the legality and compliance of the trading process while safeguarding the legitimate rights and interests of all parties involved. This cooperation not only provides a new monetization model for the Company's core data assets, but also further demonstrates the Company's expertise and market value in the field of medical imaging data.

About the Group and Beijing Rimag Information

The Group is a leading medical group specialized in medical imaging in China and the only operator and manager of a medical imaging platform that provides diversified imaging services and value to the entire medical imaging industry chain in China. The Group is principally engaged in the provision of imaging center services, imaging solution services and Rimag Cloud services. Beijing Rimag Information is a wholly-owned subsidiary of the Company. It is primarily engaged in providing Rimag Cloud and data technology services.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
Mr. CHEN Zhaoyang
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, September 2, 2025

As at the date of this announcement, the Board comprises Mr. CHEN Zhaoyang, Ms. HE Yingfei, Mr. FENG Xie and Mr. LI Feiyu as executive Directors, Mr. LIU Senlin and Mr. GUO Tao as non-executive Directors, and Mr. WU Xiaohui, Mr. LUO Yi and Ms. CHEN Yifei as independent non-executive Directors.